Abstract
Providing affordable access to essential medicines in developing countries remains a significant challenge, and it is an integral part of the global efforts to achieve Millennium Development Goals (Pécoul et al. 1999, UN.org 2015). Recent surveys show that essential medicines are available in only 58% of the healthcare facilities in the public sector and 67% in the private sector in developing countries. Also, the median prices of essential medicines are, on average, 2.92 and 4.62 times higher than international reference prices in public and private sectors respectively (MDC Gap Task Force 2015). To improve access to essential medicines, many developing countries regulate the prices of country-specific lists of essential medicines, adapted from the World Health Organization’s (WHO) model list to suit the local needs (IMS Health 2015; Hogerzeil 2004). The impact of such regulations depends as much on the design of the policy as on its implementation. Rarely if ever studies examine, in detail, the design, enforcement and compliance aspects of such price control regulations (see, for an exception, Bhaskarabhatla et al. 2016).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
International reference prices (IRPs) are median prices of quality multi-source medicines offered to low- and middle-income countries by not-for-profit and for-profit suppliers, as available from Management Sciences for Health (MSH) International Drug Price Indicator Guide (MDC Gap Task Force 2015).
- 2.
An SKU is a particular brand of medicine sold by a firm for a particular delivery and dosage form. For example, “CROCIN ADVANCE 500 MG TABLET 10” is an SKU indicating that Crocin, a popular brand of Paracetamol manufactured by GSK, contains 500 mg of the active ingredient and ten tablets in the pack.
References
Business Standard. (2015, December 10). Govt to create a separate ministry for pharma in one year: Ananth Kumar, Business Standard.
Bhaskarabhatla, A. S., Chatterjee, C., Anurag, P., & Pennings, H. P. G. (2016). Mitigating regulatory impact: The case of partial price controls on metformin in India. Health Policy and Planning, 32(2), 194–204.
Chatterjee, P. (2013). India’s patent case victory rattles Big Pharma. Lancet, 381(9874), 1263.
Francis, P. (2014a, October 22). Patented Drugs & DPCO. PharmaBiz.com
Francis, P. (2014b, July 02). Modifying DPCO 2013. PharmaBiz.com
Francis, P. (2016, November 22). Do not dismantle NPPA. PharmaBiz.com
IMS Health. (2015), Assessing the impact of price control measures on access to medicines in India. IMS Health India Report.
Kotwani, A. (2010). Access to essential medicines and standard treatment for chronic diseases. Indian Journal of Pharmacology, 42(3), 127–128.
Mathew, J. C. (2004). Paswan in favor of same profit margins for branded & generic drugs. PharmaBiz [online]. Available from http://www.pharmabiz.com/NewsDetails.aspx?aid=24757&sid=2
Mehta, P. S. (2005). Towards a functional competition policy for India. New Delhi: Academic Foundation.
McLain, S. (2014, July 15). India’s new drug-price controls: Unintended consequences? Wall Street Journal.
Nautiyal, S. (2014, September 26). Human albumin serum not available across India post NPPA price cut. PharmaBiz.com
Nautiyal, S. (2015a, March 23). NPPA may invoke para 3 of DPCO to address shortage of human albumin. PharmaBiz.com
Nautiyal, S. (2015b, May 29). Maharashtra FDA detects 5 distributors involved in overpricing of cardiac stents. PharmaBiz.com
Pécoul, B., Chirac, P., Trouiller, P., & Pinel, J. (1999). Access to essential drugs in poor countries: A lost battle? Journal of the American Medical Association, 281(4), 361–367.
Pezzola, A., & Sweet, C. M. (2016). Global pharmaceutical regulation: The challenge of integration for developing states. Globalization and Health, 12, 85.
PharmaBiz.com. (2015, July 15). Price control unlikely to improve access to medicines in India: IMS study.
Ray, T. J. (2013). New drug price control order of India: Is it directionally right improving access to medicines? [online]. Available from http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/
Saberwal, G. (2006). New pharma-biotech company formation in India. Nature Biotechnology, 24(5), 499–501.
Sell, S. (2003). Private power, public law: The globalization of intellectual property rights. Cambridge: Cambridge University Press.
Selvaraj, S. (2007). How effective is India’s drug price control regime. Boston: Harvard School of Public Health [online]. Available from https://cdn1.sph.harvard.edu/wp-content/uploads/sites/114/2012/10/RP256.pdf
Selvaraj, S. (2013, August 2). Africa could learn from India’s burgeoning pharma sector. British Medical Journal, 347, f4235.
Selvaraj, S., Farooqui, H., & Karan, A. (2018). Quantifying the financial burden of households’ out-of-pocket payments on medicines in India: A repeated cross-sectional analysis of national sample survey data, 1994–2014. BMJ Open, 8, e018020. https://doi.org/10.1136/bmjopen-2017-018020.
Shankar, R. (2014, August 21). NGOs ask government to bring more essential and lifesaving drugs under price control. PharmaBiz.com
Silverman, E. (2015, July 20). Price controls for drugs in India fail to improve access for patients: Report. Wall Street Journal.
UN Report. (2015). MDC gap task force report 2015: taking stock of global partnership for development. Economic Analysis & Policy Division. United Nations.
Vijay, N. (2017, January 18). Change to IDA from CDSCO will usher in fresh wave of accountability & professionalism: Dr Jagashetty. PharmaBiz.com
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Bhaskarabhatla, A. (2018). Introduction. In: Regulating Pharmaceutical Prices in India. India Studies in Business and Economics. Springer, Cham. https://doi.org/10.1007/978-3-319-93393-1_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-93393-1_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-93392-4
Online ISBN: 978-3-319-93393-1
eBook Packages: Economics and FinanceEconomics and Finance (R0)